GeneGo, Cystic Fibrosis Foundation To Advance Understanding Of Cystic Fibrosis

Armen Hareyan's picture
Advertisement

Cystic Fibrosis

GeneGo, Cystic Fibrosis Foundation collaborate to develop a software suite for the integration and analysis of cystic fibrosis data.

GeneGo's proprietary software combines analytical tools, data content and algorithms for understanding the complex interconnected pathways that are affected in common human diseases.

Advertisement

"We hope this collaboration will better help us to understand the disease and potential therapies at the molecular level," said Robert J. Beall, Ph.D., president and CEO of the Foundation. "Using computational platforms adds to our arsenal of already existing strategies."

The new platform, called MetaMiner (CF), will include off-the-shelf GeneGo products such as MetaCore, MetaDrug, MetaLink and MapEditor. Platforms such as MetaDrug can help to solve various problems including a drug's mechanism of action, toxicity and off-target effects, deduced from the structure and any kind of supplementary omics data. The product is intended to be used by medicinal chemists and biologists active in pre-clinical areas of high content and high throughput screening, bioassays, hit-to-lead. MetaMiner (CF) will include cystic fibrosis-specific OMICs and small experiments content annotated by GeneGo, disease maps and networks.

"We are very pleased to work with Cystic Fibrosis Foundation and the academic community which is very well organized and successful in research and drug discovery for the disease. We have a clear direction and end goals that we are focused on," said Julie Bryant, GeneGo's vice president of business development. "This collaboration is the first in the series of disease-centered MetaMiner projects which integrate our existing data analysis tools, OMICs data warehousing and disease-specific knowledge base. We have a dedicated group of Ph.D. and M.D. scientists to work on this project."

The project will be guided by a Cystic Fibrosis Foundation committee with a goal to leverage systems biology technology and accumulated data to advance drug discovery for this disease. MetaMiner (CF) is expected to be available by February of 2008 to cystic fibrosis academic researchers and drug development collaborators through access licenses.

Cystic fibrosis is a genetic disease that affects about 30,000 adults and children in the United States. It causes life-threatening lung infections and serious digestive complications. More than 10 million Americans are symptomless carriers of the CF gene.

Advertisement